10x Genomics Q2 FY26 net loss widens to $17.93 million; revenue falls to $151.04 million

Reuters2026/08/06 20:13

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

10x Genomics Q2 revenue fell to $151 million; excluding $1.6 million from a patent settlement, revenue rose 3% from Q2 2025.
Net results turned to a loss of $17.9 million; operating results swung to a loss of $19.6 million.
Gross margin widened 2 percentage points to 74%, due to lower manufacturing costs including $2.6 million of tariff refunds.
Operating expenses climbed 39% to $132.1 million, reflecting a smaller settlement gain versus the year-ago quarter.
Raised 2026 revenue outlook to $610 million-$630 million; highlighted strong early order flow for Atera, acquired Proteintech Genomics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 10x Genomics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608061602PR_NEWS_USPR_____LA21125) on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

10x Genomics Q2 FY26 net loss widens to $17.93 million; revenue falls to $151.04 million

You may also like

Crypto prices